128 Chapter 6 References 1. GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2022; 400:2221–48. 2. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 2022; 399:629–55. 3. WHO priority pathogens list for R&D of new antibiotics. 2017. Available at: http:// www. who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/. Accessed 1 November 2022. 4. Jernigan JA, Hatfield KM, Wolford H, et al. Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012–2017. N Engl J Med 2020; 382:1309–19. 5. Buis DTP, Prins JM, Betica-Radic L, et al. Current clinical practice in antibiotic treatment of Staphylococcus aureus bacteraemia: results from a survey in five European countries. J Antimicrob Chemother 2022; 77:2827–34. 6. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42:377–81. 7. McDanel JS, Roghmann MC, Perencevich EN, et al. Comparative effectiveness of cefazolin versus nafcillin or oxacillin for treatment of methicillin-susceptible Staphylococcus aureus infections complicated by bacteremia: a nationwide cohort Sstudy. Clin Infect Dis 2017; 65:100–6. 8. Miller WR, Seas C, Carvajal LP, et al. The cefazolin inoculum effect is associated with increased mortality in methicillin-susceptible Staphylococcus aureus bacteremia. Open Forum Infect Dis 2018; 5:ofy123. 9. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18–55. 10. Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for CardioThoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36:3075–128. 11. Ryder JH, Tong SYC, Gallagher JC, et al. Deconstructing the dogma: systematic literature review and meta-analysis of adjunctive gentamicin and rifampin in staphylococcal prosthetic valve endocarditis. Open Forum Infect Dis 2022; 9: ofac583. 12. Kaasch AJ, Fätkenheuer G, Prinz-Langenohl R, et al. Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO): study protocol for a randomized controlled trial. Trials 2015; 16:450. 13. Tong SYC, Mora J, Bowen AC, et al. The Staphylococcus aureus network adaptive platform trial protocol: new tools for an old foe. Clin Infect Dis 2022; 75:2027–34. 14. Bernard L, Dinh A, Ghout I, et al. Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non- inferiority, randomised, controlled trial. Lancet 2015; 385:875–82.
RkJQdWJsaXNoZXIy MTk4NDMw